December 19, 2019
Bristol-Myers Squibb submits BLA for CAR T-Cell therapy lisocabtagene maraleucel (liso-cel) to FDA
Bristol/Myers Squibb said Wednesday it has submitted a Biologics License Applications (BLA) to the FDA, which includes data from Transcend NHL 001 trial, evaluating liso-cel in patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma.